Aggresome formation and pharmacogenetics: Sulfotransferase 1A3 as a model system

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A common cause for pharmacogenetic alteration in drug response is genetic variation in encoded amino acid sequence. We have used the catecholamine and drug-metabolizing enzyme sulfotransferase (SULT)1A3 to create an artificial model system to study mechanisms-especially possible aggresome formation-by which genetic alteration in amino acid sequence might influence function. Specifically, we created a double variant SULT1A3 allozyme that included the naturally occurring Asn234 polymorphism plus an additional Trp172Arg mutation. Analysis of the SULT1A3 X-ray crystal structure had indicated that the Trp172Arg mutation might destabilize the protein's structure. Expression of SULT1A3 Arg172,Asn234 in COS-1 cells resulted in undetectable enzyme activity and a virtual lack of enzyme protein. Rabbit reticulocyte lysate degradation studies showed that the double variant allozyme was degraded much more rapidly than was wild type SULT1A3 by a ubiquitin-proteasome-dependent process. In addition, after expression in COS-1 cells, the double variant allozyme localized to aggresomes, a process not previously described or studied in pharmacogenetics. Therefore, the alteration of only one or two amino acids can lead to decreased levels of protein as a result of both aggresome formation and accelerated degradation. The possible role of aggresome formation in pharmacogenetics should be evaluated in naturally occurring systems with inherited alteration in encoded amino acid sequence.

Original languageEnglish (US)
Pages (from-to)426-433
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume325
Issue number2
DOIs
StatePublished - Dec 10 2004

Fingerprint

Sulfotransferases
Pharmacogenetics
Isoenzymes
Amino Acids
Amino Acid Sequence
COS Cells
Enzymes
Degradation
Mutation
Proteins
Reticulocytes
Enzyme activity
Proteasome Endopeptidase Complex
Ubiquitin
Polymorphism
Pharmaceutical Preparations
Catecholamines
Crystal structure
X-Rays
Rabbits

Keywords

  • Aggresome formation
  • Pharmacogenetics
  • Sulfotransferase
  • SULT1A3

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Aggresome formation and pharmacogenetics : Sulfotransferase 1A3 as a model system. / Wang, Liewei M; Yee, Vivien C.; Weinshilboum, Richard M.

In: Biochemical and Biophysical Research Communications, Vol. 325, No. 2, 10.12.2004, p. 426-433.

Research output: Contribution to journalArticle

@article{45d8e70b5d454f57bf18ea3365abab66,
title = "Aggresome formation and pharmacogenetics: Sulfotransferase 1A3 as a model system",
abstract = "A common cause for pharmacogenetic alteration in drug response is genetic variation in encoded amino acid sequence. We have used the catecholamine and drug-metabolizing enzyme sulfotransferase (SULT)1A3 to create an artificial model system to study mechanisms-especially possible aggresome formation-by which genetic alteration in amino acid sequence might influence function. Specifically, we created a double variant SULT1A3 allozyme that included the naturally occurring Asn234 polymorphism plus an additional Trp172Arg mutation. Analysis of the SULT1A3 X-ray crystal structure had indicated that the Trp172Arg mutation might destabilize the protein's structure. Expression of SULT1A3 Arg172,Asn234 in COS-1 cells resulted in undetectable enzyme activity and a virtual lack of enzyme protein. Rabbit reticulocyte lysate degradation studies showed that the double variant allozyme was degraded much more rapidly than was wild type SULT1A3 by a ubiquitin-proteasome-dependent process. In addition, after expression in COS-1 cells, the double variant allozyme localized to aggresomes, a process not previously described or studied in pharmacogenetics. Therefore, the alteration of only one or two amino acids can lead to decreased levels of protein as a result of both aggresome formation and accelerated degradation. The possible role of aggresome formation in pharmacogenetics should be evaluated in naturally occurring systems with inherited alteration in encoded amino acid sequence.",
keywords = "Aggresome formation, Pharmacogenetics, Sulfotransferase, SULT1A3",
author = "Wang, {Liewei M} and Yee, {Vivien C.} and Weinshilboum, {Richard M}",
year = "2004",
month = "12",
day = "10",
doi = "10.1016/j.bbrc.2004.10.040",
language = "English (US)",
volume = "325",
pages = "426--433",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Aggresome formation and pharmacogenetics

T2 - Sulfotransferase 1A3 as a model system

AU - Wang, Liewei M

AU - Yee, Vivien C.

AU - Weinshilboum, Richard M

PY - 2004/12/10

Y1 - 2004/12/10

N2 - A common cause for pharmacogenetic alteration in drug response is genetic variation in encoded amino acid sequence. We have used the catecholamine and drug-metabolizing enzyme sulfotransferase (SULT)1A3 to create an artificial model system to study mechanisms-especially possible aggresome formation-by which genetic alteration in amino acid sequence might influence function. Specifically, we created a double variant SULT1A3 allozyme that included the naturally occurring Asn234 polymorphism plus an additional Trp172Arg mutation. Analysis of the SULT1A3 X-ray crystal structure had indicated that the Trp172Arg mutation might destabilize the protein's structure. Expression of SULT1A3 Arg172,Asn234 in COS-1 cells resulted in undetectable enzyme activity and a virtual lack of enzyme protein. Rabbit reticulocyte lysate degradation studies showed that the double variant allozyme was degraded much more rapidly than was wild type SULT1A3 by a ubiquitin-proteasome-dependent process. In addition, after expression in COS-1 cells, the double variant allozyme localized to aggresomes, a process not previously described or studied in pharmacogenetics. Therefore, the alteration of only one or two amino acids can lead to decreased levels of protein as a result of both aggresome formation and accelerated degradation. The possible role of aggresome formation in pharmacogenetics should be evaluated in naturally occurring systems with inherited alteration in encoded amino acid sequence.

AB - A common cause for pharmacogenetic alteration in drug response is genetic variation in encoded amino acid sequence. We have used the catecholamine and drug-metabolizing enzyme sulfotransferase (SULT)1A3 to create an artificial model system to study mechanisms-especially possible aggresome formation-by which genetic alteration in amino acid sequence might influence function. Specifically, we created a double variant SULT1A3 allozyme that included the naturally occurring Asn234 polymorphism plus an additional Trp172Arg mutation. Analysis of the SULT1A3 X-ray crystal structure had indicated that the Trp172Arg mutation might destabilize the protein's structure. Expression of SULT1A3 Arg172,Asn234 in COS-1 cells resulted in undetectable enzyme activity and a virtual lack of enzyme protein. Rabbit reticulocyte lysate degradation studies showed that the double variant allozyme was degraded much more rapidly than was wild type SULT1A3 by a ubiquitin-proteasome-dependent process. In addition, after expression in COS-1 cells, the double variant allozyme localized to aggresomes, a process not previously described or studied in pharmacogenetics. Therefore, the alteration of only one or two amino acids can lead to decreased levels of protein as a result of both aggresome formation and accelerated degradation. The possible role of aggresome formation in pharmacogenetics should be evaluated in naturally occurring systems with inherited alteration in encoded amino acid sequence.

KW - Aggresome formation

KW - Pharmacogenetics

KW - Sulfotransferase

KW - SULT1A3

UR - http://www.scopus.com/inward/record.url?scp=7644241595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7644241595&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2004.10.040

DO - 10.1016/j.bbrc.2004.10.040

M3 - Article

C2 - 15530410

AN - SCOPUS:7644241595

VL - 325

SP - 426

EP - 433

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -